NICE will not accept a UPCR-only case for IgA nephropathy; eGFR slope and mandatory SGLT2i background decide NHS access.

Budesonide (Tarpeyo, Calliditas/AstraZeneca) is MHRA-approved in the UK on US-style UPCR surrogate data, but its NICE technology appraisal remains unresolved pending confirmatory eGFR data from the NefIgArd Part B extension, illustrating the core UK evidentiary gap. Sparsentan (Filspari, Travere) is under MHRA review with stronger PROTECT two-year eGFR data, slope of -2.0 versus -4.7 mL/min a year on placebo, but as a smaller company its NICE submission timeline is less certain. Neither drug has reached a positive NICE decision, so no positive UK IgAN precedent yet exists: the first drug to clear NICE will set the evidence bar every subsequent submission is measured against.

NICE's published scoping position is unambiguous: eGFR slope over at least two years is the required primary endpoint, and UPCR reduction alone, sufficient for FDA accelerated approval, will not support a positive UK technology appraisal. NICE's 2023 CKD guideline (NG203) now mandates optimised SGLT2i background therapy for any patient with UPCR above roughly 0.5g/g before a novel IgAN agent is even considered. The UK Renal Registry sizes the addressable population precisely: roughly 12,000-15,000 biopsy-confirmed IgAN patients nationally, of whom 3,000-5,000 have UPCR above threshold despite optimised background therapy and are eligible for a novel agent.

The first drug to clear NICE sets the evidence bar for every later submission.

Five questions this report answers:

Q1 - What evidence standard must a UK IgAN Phase 3 programme meet for NICE approval?

Q2 - How large is the UK IgAN population eligible for a novel agent?

Q3 - What WAC and NICE economic model make a UK IgAN submission viable?

Q4 - What deliverable formats come with a commissioned UK IgAN launch readiness assessment?

Q5 - What must a pre-launch IgA nephropathy asset prove to succeed in the UK?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#IgANephropathy #NICE #UKMarketAccess #Nephrology #LaunchReadiness

Live report page:  https://axlrx.ai/iga-nephropathy/uk/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-     hello@axlrx.ai

Web-     https://axlrx.ai/